促红细胞生成素相关药物在肾性贫血中的应用进展  

Progress in the application of erythropoietin related drugs in renal anemia

作　　者：张倩[1] 程东生[2] 汪年松[2] ZHANG Qian;CHENG Dongsheng;WANG Niansong(Department of Geriatrics,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200233,China;Department of Nephrology,Shanghai Sixth People's Hospital Affliated to Shanghai Jiao Tong University,Shanghai 200233,China)

机构地区：[1]上海交通大学医学院附属第六人民医院老年病科,上海200233 [2]上海交通大学医学院附属第六人民医院肾脏内科,上海200233

出　　处：《世界临床药物》2025年第1期14-18,共5页World Clinical Drug

基　　金：国家自然基金面上项目(82270761);国家重点研发计划(2023YFC2411803);上海市重中之重研究中心建设项目[2022ZZ01002(3)];上海市进一步加快中医药传承创新发展三年行动计划[ZY(2021-2023)-0205-04]。

摘　　要：慢性肾脏病(chronic kidney disease,CKD)一直以来是全球重要的健康问题,而肾性贫血(renal anemia,RA)是CKD重要并发症之一,其与患者全因死亡率、心血管死亡率增加均密切相关。RA的发生与红细胞生成素生成不足有关,促红细胞生成素(erythropoietin,EPO)相关药物是RA重要的治疗药物,影响CKD患者预后。现综述近年来EPO相关药物在RA中的应用进展,以期为临床提供一定参考。Chronic kidney disease(CKD)has long been an important global health problem,and renal anemia(RA)is one of the important complications of CKD,which is closely related to the increase of all-cause mortality and cardiovascular mortality in patients.The occurrence of RA is related to the deficiency of erythropoietin(EPO)production.EPO related drugs are an important treatment for RA and affect the prognosis of patients with CKD.This article reviewed the application progress of EPO related drugs in RA in recent years,in order to provide some reference for clinic.

关 键 词：促红细胞生成素 肾性贫血 慢性肾脏病 

分 类 号：R692.5[医药卫生—泌尿科学] R692[医药卫生—外科学]